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CAPSULE 30	
Two-thirds of symptomatic patients accepting a stepped-care endometriosis management were 31	
satisfied with oral contraceptives and a low-cost progestin, and few had to step up to a high-cost 32	
progestin or surgery.33	
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ABSTRACT 34	
Objective: To assess the proportion of patients with symptomatic endometriosis satisfied with their 35	
medical treatment 12 months after enrollment in a stepped-care management protocol. 36	
Design: Prospective, single-arm, self-controlled study. 37	
Setting: Academic department. 38	
Patient(s): A cohort of 157 consecutive patients referred or self-referred to our center for 39	
symptomatic endometriosis. 40	
Intervention(s): Systematic, detailed information process on medical and surgical treatment 41	
followed by a shared decision to start a stepped-care protocol including three subsequent medical 42	
therapy steps (oral contraception, [OC]; 2.5 mg/d norethindrone acetate, [NETA]; 2 mg/d dienogest, 43	
[DNG]) and a fourth surgical step. Stepping up was triggered by drug inefficacy/intolerance.  44	
Main Outcome Measure (s): Satisfaction with treatment was assessed according to a five-category 45	
scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied). 46	
Variation were measured in pain symptoms with the use of a 0-10 point numeric rating scale (NRS), 47	
in quality of life with the use of Short Form-12 questionnaire (SF-12), and in sexual functioning 48	
with the use of Female Sexual Function Index (FSFI).  49	
Result(s): At the end of the 12-month study period, 106 women were still using OC, 23 were using 50	
NETA, three were using DNG, and four had undergone surgery. Twenty-one (13%) participants 51	
dropped out from the study. In intention-to-treat analysis, excluding five drop-outs for pregnancy 52	
desire, the overall satisfaction rate with the stepped-care protocol was 62% (95/152; 95% CI, 55% 53	
to 70%). By 12-month follow-up, significant improvements were observed in all pain symptoms 54	
scores and in SF-12 physical and mental component summary scores, whereas FSFI scores did not 55	
vary substantially. 56	
Conclusion(s): Most women with endometriosis-associated pelvic pain who chose a stepped-care 57	
approach, were satisfied with OC and a low-cost progestin for the treatment of their symptoms. The 58	
need to step up to an expensive progestin or surgery was marginal. 59	
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INTRODUCTION 61	
According to the opinion of the Practice Committee of the American Society for Reproductive 62	
Medicine on treatment of endometriosis-associated pelvic pain, "endometriosis should be viewed as 63	
a chronic disease that requires a lifelong management plan with the goal of maximizing the use of 64	
medical treatment and avoiding repeated surgical procedures" (1).  65	
 In fact, surgery for endometriosis is reportedly effective for pelvic pain, but postoperative 66	
recurrence of symptoms and lesions is as high as 40-50% at 5-year follow-up (2-4). Moreover, 67	
removal of ovarian endometriomas is associated with reduction of ovarian reserve (5,6), and 68	
excision of deep infiltrating forms is associated with a relatively high incidence of complications, 69	
especially when rectovaginal and bowel lesions are present (3,7,8). Outcomes of complex surgical 70	
procedures are strictly operator dependent and therefore scarcely reproducible. Finally, surgery is 71	
expensive. For these reasons, many women would leave surgery as the second choice, only in case 72	
medications are ineffective or not tolerated (9).  73	
 Based on secondary research findings (10) and according to guidelines issued by several 74	
international gynecologic societies, hormonal compounds to treat endometriosis have similar effects 75	
on pain, but different metabolic and subjective side-effects and costs (1, 11-14). Therefore, in 76	
women who prefer medical rather than surgical treatment, those drugs with the most favorable 77	
therapeutic profile and lower cost should be used first, stepping up to drugs with a less favorable 78	
therapeutic profile or higher cost selectively in those patients who do not respond or do not tolerate 79	
the first-line medications.  80	
 Despite decades of intensive clinical research, the ultimate prognosis of a woman with 81	
symptomatic endometriosis who chooses prolonged medical treatment with first-line drugs instead 82	
of surgery is currently unknown. In other words, the likelihood that a woman will succeed in 83	
successfully controlling her complaints and be satisfied with her treatment without having to step-84	
up to second-line compounds and eventually to surgery is currently undefined. The answer to this 85	
practical question seems crucial for informing patient decisions. Even women preferring medical 86	
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rather than surgical treatment may choose differently in case the risk of having to resort anyway to 87	
surgery is high. 88	
 Given this unclear scenario, we deemed it of interest to assess the trajectory of an unselected 89	
cohort of consecutive endometriosis patients through a pre-planned stepwise therapeutic protocol 90	
including three subsequent medical steps (oral contraception, [OC];  norethindrone acetate, 91	
[NETA]; dienogest, [DNG];) and a fourth, final, surgical step. The main objective of the 92	
investigation was to estimate the probability of being satisfied with this stepped medical care 93	
approach 1 year after starting the use of a low-dose OC.  94	
MATERIALS AND METHODS 95	
This study was conceived and designed, the results interpreted, and the report written, together with 96	
representatives of a large Italian nonprofit endometriosis patient association (Associazione Progetto 97	
Endometriosi Onlus), and it was conducted within the framework of a participatory research 98	
initiative aimed at prioritizing topics and research questions that patients consider to be important. 99	
Engaging patients in the design of a new pragmatic study model on endometriosis management was 100	
deemed to be crucial to capturing aspects of health and functioning that matter to them.   101	
 The manuscript was prepared according to the Strengthening the Reporting of Observational 102	
studies in Epidemiology guidelines for reporting observational studies (15). The investigation was 103	
performed in an academic department specializing in endometriosis management, and the relevant 104	
Institutional Review Board approved the study (Comitato di Etica Milano Area B, determination 105	
no.903/2015). Every patient signed an informed consent form before enrollment. 106	
Design 107	
A prospective, single-arm, self-controlled, observational study design was adopted. The main 108	
objective was to assess the degree of satisfaction with a stepped medical treatment care in a cohort 109	
of consecutive patients with symptomatic endometriosis starting therapy with an OC used 110	
continuously, and sequentially stepping up to NETA and then to DNG in case of drug inefficacy or 111	
intolerance. Secondary objectives were the evaluation of within-person variations in pain 112	
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symptoms, health-related quality of life, and sexual function after 12 months, as well as of the 113	
proportion of patients eventually needing to step up to surgery. With this study design each 114	
participant acted as her own control, to avoid the potential confounding caused by differences 115	
between patients (16). In fact, variations in satisfaction with treatment was not assessed after a pre-116	
planned shift to another drug in a general population of patients taking OC, but specifically in those 117	
patients who stepped up to a second- or third-line medication owing to dissatisfaction with, 118	
respectively, OC or NETA because of inefficacy or intolerability, and who would otherwise have 119	
discontinued medical therapy.  120	
Study participants 121	
We considered 18- to 40-year-old women, not seeking conception, with a surgical diagnosis of 122	
ovarian and/or deep endometriosis or a current nonsurgical diagnosis of ovarian and/or deep 123	
endometriosis (17), consecutively referred or self-referred to our tertiary-care endometriosis center 124	
because of moderate or severe pelvic pain symptoms of >6 months’duration. Those patients who 125	
were already using any type of pharmacologic therapy and were satisfied with their treatment were 126	
not considered for enrollment. 127	
 Nonsurgical diagnoses were based on ultrasonographic criteria in patients with ovarian 128	
endometriomas (18,19); on visual inspection of the posterior fornix and biopsy of vaginal lesions in 129	
those with rectovaginal endometriosis (20,21); on ultrasonographic criteria (22), cystoscopic 130	
findings, and biopsy of vesical lesions in those with bladder detrusor endometriosis; on physical 131	
signs at rectovaginal examination and ultrasonographic criteria (23,24) in those with deep lesions 132	
infiltrating the Douglas pouch and parametria; and on ultrasonographic criteria (24), double-133	
contrast barium enema, and, in some women, rectosigmoidoscopy or colonoscopy findings in those 134	
with full-thickness bowel lesions. Magnetic resonance imaging was performed in selected 135	
circumstances. The ultrasonographic diagnosis of adenomyosis was based on detection of 136	
asymmetric thickness of the anterior and posterior uterine walls, heterogeneous myometrial 137	
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echotexture, and round anechoic areas and hypoechoic linear striations within the myometrium  138	
(25). 139	
 Patients were excluded in case of obstructive uropathy or subocclusive bowel stenosis, 140	
evidence of complex adnexal cysts or a unilocular ovarian endometrioma with a diameter > 4 cm at 141	
vaginal ultrasonography, the typical contraindications to OC and progestins, a diagnosis of 142	
concomitant disorders that may cause pelvic pain independently of endometriosis presence (e.g., 143	
pelvic inflammatory disease or pelvic varices or genital malformations at previous surgery; known 144	
urologic and orthopedic diseases), psychiatric disturbances, and history of drug or alcohol abuse. 145	
From August 2015, all new endometriosis patients consecutively referred or self-referred to our 146	
center were evaluated for eligibility, and recruiting continued until the pre-planned sample size was 147	
reached in January 2016. 148	
The information process  149	
In our center, all women are thoroughly informed regarding the possible treatment options for their 150	
clinical condition on the base of up-to-date literature evidence, with priority given to the best-151	
quality primary and secondary research available (26). The information is expressed quantitatively 152	
with the use of absolute numbers (e.g., crude percentages with a consistent denominator, such as 153	
100 treated), and avoiding the use of estimates that may not be easily understood (e.g., relative 154	
risks), and it is provided in both verbal and written form. The communication session between the 155	
physician and the patient has no predetermined time limits. Medical and surgical treatments are 156	
described in detail and both are offered as available options.  157	
 Before deciding whether to start medical therapy or undergo surgery, women were informed 158	
that OC is considered by some authors to be the first line treatment for endometriosis-associated 159	
pelvic pain, but that further medical therapy steps are available in case of inefficacy or intolerance. 160	
They were also informed that medical therapies for endometriosis are usually effective in reducing 161	
various types of pain in about two thirds of patients (27-29). However, drugs induce only temporary 162	
relief, are not expected to be definitively curative, and may cause several side effects (listed, with 163	
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percentages derived from previous studies conducted in our center). Finally, when hormonal 164	
treatments are to be continued for long periods, estrogen-progestins and progestins appear to be 165	
among the compounds that most favorably balance benefits, harms and costs (30,31). In particular, 166	
the continuous use of OC is suggested to achieve amenorrhea and relieve pain at withdrawal 167	
bleeding that may still afflict endometriosis patients using OC cyclically (32,33). 168	
 It was explained that the estrogen included in OC on one hand may prevent potentially 169	
detrimental effects of hypoestrogenizing treatments (e.g., vaginal dryness, decrease in bone mineral 170	
density, and unfavorable modifications in serum lipid pattern), but on the other hand may limit the 171	
therapeutic efficacy on endometriotic implants that, being estrogen sensitive, may retain part of 172	
their metabolic activity. Thus, in case of symptom persistence, a shift to a progestin monotherapy 173	
may improve pain. This change of medication may be of benefit also in case of intolerance to OC, 174	
because the estrogen component is generally associated with specific side-effects (e.g., headache) 175	
(34). Differences in the effect on pain and in side-effects may exist even among different 176	
progestins. Therefore, changing from NETA to DNG may relieve symptoms to a greater extent, or 177	
untoward effects may subside. However, the likelihood and magnitude of these potential variations 178	
are scarcely quantifiable owing to limited available evidence. Moreover, NETA is very cheap, 179	
whereas DNG is costly.  180	
 Women were informed that other drugs for symptomatic endometriosis were available but 181	
that, owing to important untoward effects and/or high costs, generally they were not suggested for 182	
prolonged treatment periods. Finally, patients were also informed that laparoscopic surgery was a 183	
reasonable alternative associated with a 70-80% probability of partial or complete pain relief in case 184	
they declined medical therapy or switching from OC to a progestin, but that the risk of pain and 185	
lesion recurrence was ~10% per year without long-term postoperative medical treatment (2-3), they 186	
were also informed that, in case of excisional procedures for rectovaginal lesions, surgery is 187	
associated with major complications in ~10% of cases (listed, with percentages derived from 188	
published primary and secondary research). Finally, it was explained that repeat surgery, owing to 189	
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the presence of adhesions distorting abdominal-pelvic anatomy, may become less effective against 190	
pain as well as riskier, although precise estimates may not be provided because of paucity of 191	
published data. 192	
Interventions: the stepped care approach 193	
Women who chose medical therapy were invited to start a low-dose, monophasic OC used 194	
continuously (Step 1). During the enrollment period, the OC used in our center was a monophasic 195	
formulation containing 0.015 mg ethinyl-estradiol (EE) and 60 mg gestodene or, in case of spotting, 196	
0.02 mg EE and 150 mg desogestrel. In smokers and in those with a body mass index (BMI) ≥ 30 197	
kg/m2, a combination of 0.02 mg EE and 100 mg levonorgestrel was prescribed.  198	
 All patients underwent clinical and ultrasonographic evaluations at 3, 6, and 12 months after 199	
enrollment, unless required otherwise because of pain recurrence or insurgence of untoward effects. 200	
On these occasions, the women were asked to complete questionnaires on pain, quality of life, and 201	
sexual functioning. They were also asked to indicate drug tolerability and to rate the degree of 202	
overall satisfaction with their treatment. Whenever a participant was dissatisfied with OC because 203	
of inefficacy for pain or intolerable side effects, she was counseled again and invited to consider 204	
stepping up to NETA or undergoing surgery. Dissatisfied women who chose to continue with 205	
medical treatment started NETA at the dose of 2.5 mg orally once a day, (Step 2), after 4 or 7 days 206	
off OC, depending on the type being used. Norethindrone acetate, a 19-nortestosterone-derivative 207	
progestin, has been repeatedly evaluated in women with endometriosis (35-41), and has been 208	
successfully used in our referral center for several years (20,21,42).  209	
 When a participant was dissatisfied with NETA because of inefficacy for pain or intolerable 210	
side-effects, she was counseled again and invited to consider stepping up to DNG or undergoing 211	
surgery. Those women who chose to continue with medical treatment started DNG immediately at 212	
the dose of 2 mg orally once a day, (Step 3). Dienogest, a semisynthetic 19-nortestosterone-213	
derivative progestin, has been investigated and registered also for the treatment of endometriosis. Its 214	
effect on pain was demonstrated to be significantly superior to placebo and equivalent to a GnRH 215	
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analogue (43,44). Moreover, DNG was particularly well tolerated by women with symptomatic 216	
endometriosis (43,44). Women were informed that DNG was indicated as step 3, instead of step 2, 217	
because DNG is much more expensive that NETA and may have an adverse impact on bone 218	
mineral density (43,45). 219	
 In case of prolonged spotting (≥ 7 days) or breakthrough bleeding, the patients were advised 220	
to discontinue treatment for 1 week (4 days in case of OC containing 0.015 mg EE and 60 mg 221	
gestodene). When needed, naproxen sodium was the standard nonsteroidal antiinflammatory drug 222	
prescribed (one 550-mg tablet twice a day unless contraindicated). 223	
  When a participant was dissatisfied also with DNG because of inefficacy for pain or 224	
intolerable side-effects, she was counseled again and invited to consider undergoing surgery (Step 225	
4).  However, surgery could be chosen by women also during OC or NETA use in case they 226	
declined continuing with the stepped-care protocol. Laparoscopic treatment of endometriosis was 227	
performed with mechanical and electrosurgical instrumentation according to standard and already 228	
described techniques aiming at excising all endometriotic lesions and restoring a normal pelvic 229	
anatomy (46-49). Participants who underwent surgery were regularly followed after the procedure. 230	
Measurements 231	
The presence and severity of dysmenorrhea, deep dyspareunia, nonmenstrual pelvic pain, and 232	
dyschezia were assessed with the use of an 11-point numeric rating scale (NRS), with 0 indicating 233	
absence of pain and 10 pain as bad as it could be. Patients were considered for enrollment if they 234	
complained of at least one moderate-to-severe pain symptom (points 6-8, moderate pain; point 9 or 235	
10, severe pain). Irregular bleeding during treatment was defined as spotting (scanty bleeding 236	
requiring no more than one pad or tampon per day) or breakthrough bleeding (light or moderate 237	
bleeding requiring two or more pads or tampons per day). Pain during spotting or breakthrough 238	
bleeding was considered to be dysmenorrhea.  239	
 Quality of life was assessed with the use of the Short Form-12 (SF-12) health survey, a well-240	
known and validated self-administered 12-item instrument developed from the original SF-36 241	
Vercellini et al., 14	
questionnaire (50,51). It measures health dimensions covering functional status, well-being, and 242	
overall health. Information from the 12 items is used to construct physical and mental component 243	
summary measures (52,53), with higher scores indicating better health perception. 244	
 The Female Sexual Function Index (FSFI) questionnaire is a 19-item, multidimensional, 245	
self-report instrument for evaluating the main categories of female sexual dysfunction and sexual 246	
satisfaction (54,55). Domains include desire, arousal, lubrication, orgasm, satisfaction, and pain. 247	
Each domain is scored on a scale of 1 to 5, and the maximum transformed full-scale score is 36, 248	
with a minimum transformed full-scale score of 2.0. Women with an FSFI total score <26.55 are 249	
categorized as experiencing sexual dysfunction (56).  250	
 Patients rated the degree of satisfaction with their treatment according to a five-category 251	
scale (very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, very dissatisfied) by 252	
answering the following question: “Taking into consideration the variations occurring in pain 253	
symptoms, overall physical and psychologic well-being, and sexual functioning, how would you 254	
define the level of satisfaction with your current treatment?”.  255	
Data management 256	
Based on our previous experience, the proportion of endometriosis patients satisfied with OC 257	
treatment is ~ 65% (20,57). The study hypothesis was that the application of a stepwise treatment 258	
approach, which includes the possibility of stepping up to NETA and then to DNG, could increase 259	
this proportion to 80%. In our view, decreasing the dissatisfaction rate from one out of three to one 260	
out of five women would be a clinically important difference. Based on the Wald method for a 261	
binomial distribution, 150 participants were needed to limit the confidence interval (CI) around the 262	
point estimate (80%) to 74%-86%. 263	
 Data were archived in Excel 2003 (Microsoft Corp.) and exported to SPSS 18.0, for 264	
statistical analysis. Estimate of patient satisfaction rate was performed according to the intention-to-265	
treat principle, considering as dissatisfied all patients who dropped out of the study for any reason 266	
except conception seeking, thus including request for not pre-planned medical therapies or need for 267	
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surgery, as well as loss to follow-up. To limit the potential effect of confounding, satisfaction with 268	
treatment, was dichotomized into “satisfied” (very satisfied plus satisfied) and “dissatisfied” 269	
(neither satisfied nor dissatisfied plus dissatisfied plus very dissatisfied). 270	
 Variations in pelvic pain symptoms, health-related quality of life, psychologic status, and 271	
sexual functioning between baseline and 12-month values were evaluated by means of the paired 272	
Student t test for normally distributed data (age, BMI, FSFI, SF-12), the non-parametric Wilcoxon 273	
matched pairs test for nonnormally distributed data (NRS scores and number of days with 274	
considerable pain or impairment of usual activity), the McNemar test for categoric variables, and 275	
the Fisher Exact test in case of cells without numeric data. Per-protocol analyses were adopted for 276	
secondary end points. Determinants of satisfaction with treatment were investigated with unpaired 277	
tests (Student t test for normally distributed continuous variables, Wilcoxon test for nonnormally 278	
distributed continuous variables, and chi-square test for categoric variables). The multivariate 279	
analysis to evaluate the independent role of the variables predictive for satisfaction with treatment 280	
was performed with the use of a logistic regression model. Specifically, those variables that were 281	
found to significantly differ at univariate analysis were included in the model. All statistical tests 282	
were two sided. A P value < .05 was considered to be statistically significant. When appropriate, 283	
95% CIs were calculated for the observed differences by applying a binomial distribution model. 284	
 285	
RESULTS 286	
A total of 186 women were deemed to be eligible during the study period, but 29 (16%) declined 287	
enrollment: 20 opted for cyclic OC use and nine for immediate surgery. The remaining 157 women 288	
were recruited for the study (Fig.1). The baseline demographic and clinical characteristics of the 289	
patients are presented in Table 1. One-Half of the women previously underwent surgery for 290	
endometriosis, and more than two-thirds previously used some medical therapies. A total of 64 291	
patients (41%) had deep endometriotic lesions (rectovaginal, 56; other, 8), and 64 (41%) had 292	
ovarian endometriomas (unilateral, 51, bilateral, 13). The median (interquartile range [IQR]) largest 293	
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deep lesion diameter was 15(10-20) mm (largest lesion diameter, 43 mm), and the median (IQR) 294	
largest endometrioma diameter was 26 (19-38) mm (largest endometrioma diameter, 40 mm). 295	
Thirty-three women (21%) had an ultrasonographic diagnosis of uterine adenomyosis 296	
(Supplemental Table 1). No statistically significant differences were observed in baseline 297	
characteristics between women who accepted and those who declined enrollment into the study 298	
(data not shown).  299	
Participant progress through the stepped-care protocol 300	
Of the recruited 157 patients, 14 (9%) requested shifting to NETA (Step 2) within 3 months after 301	
start of OC use (Step 1), because of inefficacy for pain (n = 5) or drug intolerance (n = 9), and one 302	
requested surgery (Step 4) because of pain persistence. During the same time period, five 303	
participants dropped out of the study (requested cyclic OC use because of intolerance to continuous 304	
use, n = 3; declined further treatments, n = 1; lost to follow-up, n = 1; Fig.1). At 6-month 305	
assessment, 11 women had shifted from OC to NETA, and another two from NETA to DNG 306	
because of inefficacy for pain (n = 7) or drug intolerance (n = 6). Two women taking OC underwent 307	
surgery because of endometrioma growth. Seven patients dropped out between the 3- and 6-month 308	
evaluations (declined further treatment, n = 3 (OC, n = 2; NETA, n = 1); requested cyclic instead of 309	
continuous OC use, n = 2; pregnancy desire, n = 2 (OC, n = 1; NETA, n = 1)). Within the 12-month 310	
assessment, six women shifted from OC to NETA and two from NETA to DNG, because of 311	
inefficacy for pain (n = 5) or drug intolerance (n = 3) and one from DNG to surgery because of 312	
inefficacy for pain. In the same time frame, nine patients dropped out of the study (pregnancy 313	
desire, n = 3 (all OC); requested cyclic instead of continuous OC use, n = 2; declined further 314	
treatments, n = 2 (OC, n = 1; NETA, n = 1); lost to follow-up, n = 2 (OC, n = 1; NETA, n = 1)).  315	
 At the end of the 12-month study period, 106 women were still using OC, 23 were using 316	
NETA, three were using DNG, and four women had undergone surgery (including one who 317	
requested surgery at the 12-month evaluation, after completion of the pre-planned 1-year medical 318	
treatment period). Overall, 21 participants (13%) dropped out from the study, ten because of drug 319	
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intolerance (seven requested a shift from continuous to cyclic OC use and three declined further 320	
treatments), five because of pregnancy desire, three because of phychologic intolerance to hormonal 321	
therapies (they all declined further treatments), and three were lost to follow-up. The seven women 322	
who requested to use OC cyclically instead of continuously, continued a medical treatment, but not 323	
with the modality pre-planned for the stepwise protocol. For this reason, they were included among 324	
dropouts. 325	
Pain symptoms, health-related quality of life, and sexual functioning 326	
A per-protocol analysis was conducted on the 133 women who completed the study (132 women 327	
who continued medical treatment plus one who used medical treatment for 1 year and requested 328	
surgery only at final 12-month evaluation). Highly statistically significant reductions in NRS score 329	
were observed for all of the symptoms considered (Table 2). At the end of study period, the 330	
prevalence of moderate or severe pain decreased from 94% to 12% for dysmenorrhea, from 59% to 331	
30% for deep dyspareunia, from 43% to 12% for dyschezia, and from 44% to 23% for 332	
nonmenstrual pelvic pain. The median (IQR) number of days with pain necessitating analgesics 333	
decreased from 7(4-10) to 0(0-2) per month, and the number of days with impairment of usual 334	
activities decreased from 2(0-4) to 0(0-0). 335	
 Significant improvements in summary scores for both, the physical (from 41.4 ± 11.1 to 336	
51.0 ± 8.7) and the mental (from 41.9 ± 10.5 to 47.0 ± 10.0) SF-12 components were observed (P < 337	
.001). A trend toward a marginal worsening of the FSFI score was observed (Table 2). 338	
 The incidence and types of untoward effects reported at pre-planned visits by women using 339	
medical treatments are presented in Table 3. Side-effects were experienced by about four out of five 340	
patients, but their severity determined drug discontinuation in only ten participants, seven of whom 341	
requested shifting from continuous to cyclic OC use.  342	
Satisfaction with treatment  343	
 At the 12-month assessment, 95 of the 133 participants who completed the stepwise protocol 344	
were satisfied with their treatment (71%; 95% CI, 63%-79%). At the same time point, 38 women 345	
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declared that they were dissatisfied (OC, n = 29; NETA, n = 8; dienogest, n = 1), but only two of 346	
them requested surgery. An intention-to-treat analysis was conducted on 152 patients, instead of the 347	
157 enrolled, because five women dropped out of the study before the 12-month evaluation not 348	
because of drug inefficacy or intolerance, but because of pregnancy desire. Considering all 349	
remaining drop-outs and women who underwent surgery as dissatisfied, the overall satisfaction rate 350	
was 62% (95/152; 95% CI, 55%-70%). However, seven drop-outs continued using OC, though 351	
cyclically instead of continuously and six of them were satisfied with their treatment at 12-month 352	
follow-up. Considering those seven women still under treatment would result in a less conservative, 353	
but more realistic satisfaction rate of 66% (101/152; 95% CI, 59%-73%). 354	
 Baseline demographic and clinical characteristics of the 95 satisfied and 57 dissatisfied 355	
patients in the intention-to-treat analysis, were substantially similar. In univariate analysis, 356	
statistically significant differences were observed only for BMI and the SF-12 mental component 357	
summary score, which were, slightly higher and lower, respectively, in the group of dissatisfied 358	
women  (Supplemental Table 2). In the logistic regression model, both BMI and the SF-12 mental 359	
component summary score remained significantly associated with satisfaction with treatment (P = 360	
.033 and .043, respectively).  361	
 362	
DISCUSSION 363	
According to the findings of this self-controlled study conducted prospectively on a cohort of 364	
consecutive patients with symptomatic endometriosis who chose medical therapy as their preferred 365	
treatment, the probability of stepping up to an expensive progestin (Step 3) because of intolerance 366	
to NETA or to undergo surgery (Step 4) for any reason, was very limited. About two participants 367	
out of three were satisfied with the proposed stepped medical care approach after 12 months. This 368	
result was obtained with OC used continuously in the entire cohort of 157 women, NETA in 31 369	
(20%), and DNG in four (3%). Surgery was needed in four women (3%), but in two of them the 370	
indication was the unexpected growth of an ovarian endometrioma, not inefficacy of the drugs.  371	
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 Unexpectedly, of the 38 women who declared themselves to be dissatisfied with medical 372	
treatment, only two requested surgery, and the other 36 preferred to tolerate reduced but persistent 373	
pain or some side-effects rather than undergo surgery. However, when pragmatically considering 374	
the impact of medical treatment at large, also those 29 women who did not accept the stepped-care 375	
protocol and requested cyclic OC use (n = 20) or immediate surgery (n = 9) should be considered. 376	
Based on this conservative approach, surgery was eventually required in 13 (4 + 9) out of 186 (157 377	
+ 29) patients (7%). Moreover, when planning the study, we hypothesized that 80% of women 378	
would had been satisfied with the stepped-care medical approach, but this was not the case. In the 379	
best scenario, that is, not excluding women who shifted from continuous to cyclic OC use, the 380	
proportion of satisfied women was 66%, thus not superior to that repeatedly observed by us when 381	
evaluating monotherapies. We recruited a series of consecutive women with endometriosis seeking 382	
care for their pain symptoms, and what we have observed might provide an overall representation 383	
of what unselected women can expect from medical treatment in the real world. These figures will 384	
now be used in our practice when informing patients during the shared decision-making process, 385	
specifying that the above estimates do not apply to the general population of women with 386	
symptomatic endometriosis, but specifically to those women who choose medical rather than 387	
surgical treatment. 388	
 We excluded women with endometriomas >4 cm. However, the maximum cyst diameter for 389	
which surgery may be safely avoided in patients aged ≤ 40 years is currently undefined. Until a 390	
consistent cutoff is indicated in guidelines issued by major scientific societies, the diameter of 5 cm 391	
suggested by Muzii et al. (58) may be more appropriate in women with typical endometriomas. 392	
Periodic evaluations are nevertheless recommended to detect in a timely manner possible 393	
modifications of ultrasonographic cyst characteristics or unexpected growth during ovarian 394	
suppression (58). 395	
 We deemed it to be important to describe in detail the information provided to patients, as 396	
well as the standard shared decision-making process systematically adopted in our center, because a 397	
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strong relationship seems to exist between the characteristics of specific "centers of expertise", and 398	
the treatment chosen (i.e., medical or surgical) by patients referred to those centers. It may not be 399	
excluded that the type of information provided largely determines the final patient decision 400	
(26,59,60). According to Head et al. (61) “certain details of alternate treatments can intentionally 401	
or unintentionally be omitted, resulting in a failure to allow the patient to make a well informed 402	
decision”. Therefore, in our view, the description of the information process should be included in 403	
the methodologic section of future interventional trials for symptomatic endometriosis. In our 404	
experience, when thoroughly informed on potential benefits, harms, and drawbacks of medical and 405	
surgical treatments, most women not seeking conception express their preference for the former 406	
option (21), thus confirming that patients who engage in shared decision-making tend to choose 407	
nonsurgical treatment alternatives (62). Of relevance here, both medical and surgical treatments for 408	
all endometriosis forms are available in our center and offered to patients. 409	
 The self-controlled design may appear to be a limitation of our study. However, this model 410	
was chosen because our aim was not to conduct head-to-head comparisons between available 411	
treatment options, but rather to evaluate sequentially the effect of different drugs used as a second- 412	
or third-line therapy specifically in nonresponders to OC. In this setting, participants acted as their 413	
own control, thus limiting the effect of confounding associated with different distribution among 414	
patients of relevant characteristics that can influence study outcomes (16). Moreover, the adoption 415	
of an intention-to-treat analysis to assess patient satisfaction, and including as dissatisfied all 416	
participants who underwent surgery and all drop-outs except women who discontinued treatment to 417	
seek a conception should have avoided overoptimistic results which are generally associated with 418	
observational study designs. 419	
 Theoretically, the "regression toward the mean" phenomenon could have affected the 420	
observed data, because extreme values are frequently influenced by random variation and, when 421	
remeasured they tend to be closer to the mean of the original population from which the study 422	
subjects were drawn (32,63). Therefore, when the patients’ conditions are worse than average and 423	
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standard therapies seem to have lost efficacy, some general amelioration may occur that has nothing 424	
to do with improved treatment (32,63). However, the magnitude of this effect should have been 425	
limited here, because we recruited women complaining of chronic and fairly stable pain symptoms 426	
that were measured on more than one occasion during the pre-enrollment phase and throughout the 427	
study period (63). Also, a carry-over effect could not be excluded when stepping up because of drug 428	
inefficacy or intolerance. However, in such a case the effect would have been negative and led to a 429	
decrease in the patient satisfaction rate.  430	
 Selection bias could have influenced our findings, because choosing to enter the stepped-431	
care protocol in fact created a self-selection favoring hormonal therapy. This limits the 432	
generalizability of our results to those women who prefer medical rather than surgical treatment. On 433	
the other hand, recruiting consecutively all eligible patients referred to our center in a defined study 434	
period should have limited these study drawbacks. Furthermore, the demographic and clinical 435	
characteristics of women who accepted and refused entering the stepwise protocol were similar. 436	
 More in general, it may not be excluded that patients self-referring to our center are not 437	
representative of the general population of women with endometriosis, because they may be more 438	
prone to start medical therapies rather than request surgery. In fact, many patients may now easily 439	
identify through the Internet and patient association websites those referral centers that are in favor 440	
of medical treatment. However, this is a problem also for studies conducted in centers adopting 441	
mainly a surgical approach. In addition, the attitude of the personnel of our center toward discussing 442	
benefits and harms of all available treatment options, and the systematic application of a shared 443	
decision-making process, may have had per se a psychologic effect, because women likely felt 444	
understood and supported, although we did not measure such aspects. In theory, outcomes may vary 445	
in centers applying different approaches regarding patient information and decision-making. 446	
Nevertheless, a mere placebo effect, typically lasting no longer than a few weeks (64), seems 447	
unlikely, given the relatively prolonged treatment period. 448	
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 Health-related quality of life and sexual functioning were measured with the use of widely 449	
used and reliable scales. The clinical validity and internal consistency of the SF-12 have been 450	
demonstrated in large samples in many countries, including Italy (53,65). Both the physical and the 451	
mental components of health-related quality of life, as measured by this instrument, were 452	
substantially improved with the use of medical treatment. 453	
 The FSFI also has been validated and demonstrated acceptable internal consistency and test–454	
retest reliability (55,56). A marginal worsening of the FSFI scores from baseline to 12-month 455	
assessment was observed. In our experience, significant improvements of sexual functioning as 456	
measured by the FSFI were associated with progestin monotherapy (42,66). However, deep 457	
dyspareunia persisted in ~30% of our patients. We speculate that OC, used by most of the study 458	
participants, may exert a smaller effect on pain at intercourse owing to the estrogen component that 459	
may impede complete metabolic inhibition of endometriotic foci (67). Moreover, it has been 460	
demonstrated that OC may adversely affect desire, arousal, and pleasure (68). 461	
 The incidence of side effects of OC and progestins was surprisingly high. However, 462	
occurrence of side-effects associated with medical treatments was actively investigated by research 463	
fellows, and this may have lead (non è LED?) to listing even mild disturbances that otherwise 464	
would not have been reported. Overall, untoward effects caused drug discontinuation in fewer than 465	
one out of 10 ten patients, so most complaints were not severe enough to induce women to request 466	
surgery. 467	
 Finally, representatives of a major national endometriosis patient association were 468	
coinvestigators in this study. Partnership between patient associations and clinical investigators 469	
seems to be important to move forward patient-centered research and ameliorate patient care. 470	
Engaging patients for research on endometriosis management may help in defining those priorities 471	
that are most important to them, at the same time advancing truly shared decision making (69-71).  472	
  473	
CONCLUSIONS 474	
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 The results of this prospective, self-controlled study suggest that most women with 475	
symptomatic endometriosis were satisfied with OC and a low-cost progestin, and that only a small 476	
minority of them actually needed a costly progestin or requested surgery to control pelvic pain. 477	
Replication of our findings by other investigators is advisable, because the observed results may be 478	
valid only for patients who prefer medical rather than surgical treatment, and may not be 479	
generalizable to all patients with endometriosis.  480	
 In Italy, the yearly cost of treatment with the OC combinations used in our study is $188-481	
197 / €159-167 / £146-154, with NETA is $20 / €17 / £16, and with DNG is $861 / €730 / £672. 482	
Thus, the use of low-dose OC and low-cost progestins for endometriosis management may be 483	
termed "high-value care" (72). The value of a medical intervention is the balance between its 484	
potential benefits, potential harms, and costs, combined with the priorities and preferences of 485	
individual patients. Value also conveys the dimension of the amount of care gained per each dollar 486	
spent (72).  487	
 When correctly used in women without major contraindications, OC is very safe (73-76). 488	
Thus, despite some limited drawbacks in terms of efficacy and tolerability (34,67), OC could retain 489	
its role in the current therapeutic armamentarium for women with endometriosis (77,78). However, 490	
those OC combinations with the lowest estrogen content (79-81) and associated with the smallest 491	
amount of withdrawal bleeding (33) should be used and further investigated (77). Progestins may be 492	
preferred in patients with deep infiltrating lesions (82). 493	
 According to the Institute of Medicine, clinical practice and research must be integrated to 494	
define "what work best for whom in order to inform decisions that lead to safe, efficient, effective, 495	
and affordable care" (83). The results of explanatory randomized controlled trials (RCTs) aimed at 496	
defining the effect of experimental treatments may not be directly transferable to all patients, 497	
because when treating a chronic disorder for years, the effect on pain is one among several factors 498	
to be considered. Safety, tolerability, as well as costs for individual women and for the health care 499	
system also should be taken into account. In other words, if a new drug has a demonstrated large 500	
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effect on pain, this does not mean that all patients with endometriosis should use that drug if its 501	
safety and tolerability are no better than those of existing alternatives, but its cost is much higher. In 502	
the words of Greenhalgh "randomised controlled trials may constitute the ideal of experimental 503	
design, but they alone can not prove that the right intervention has been provided to the right 504	
patient at the right time and place"(84). Moreover, patients encountered in everyday practice may 505	
have different characteristics from those enrolled in explanatory RCTs.  506	
 The advent of new drugs for endometriosis (85-88) is very welcome, because this means 507	
that patients will have another treatment option for managing their pain as an alternative to surgery. 508	
Nevertheless, if new drugs are less safe or more expensive than existing ones, they should not be 509	
prescribed to all women with symptomatic endometriosis, but solely in those who do not respond or 510	
do not tolerate low-dose OC and low-cost progestins. Therefore, the evaluation of various stepwise 511	
treatment protocols may be suggested with the objective of increasing the value of care for women 512	
with endometriosis.  513	
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Table 1. Baseline demographic and clinical characteristics of the 157 women enrolled in the study.  
  
 Characteristic Data 
  Age (y)           32.9 ± 5.7 
Age (y) at first diagnosis            27.4 ± 5.4 
BMI (kg/m2)           21.6 ± 3.5 
Previous deliveries  34 (22) 
Previous interventions for endometriosis 
 None  78 (50) 
1  58 (37) 
2              15 (9) 
≥ 3 6 (4) 
Previous medical therapy a 
 None   35 (22) 
Estrogen-progestins b 115 (73) 
Progestins b   23 (15) 
GnRH analogues   3 (2) 
Dysmenorrhea 
 NRS  9 (8-10); 8.6 ± 4.5 
NRS > 5 148 (94) 
Dyspareunia c 
 NRS    6 (0-8); 5.1 ± 3.3 
NRS > 5   85 (61) 
Dyschezia 
 NRS    2 (0-8); 3.7 ± 3.9 
NRS > 5   65 (41)  
Nonmenstrual pelvic pain 
 NRS         5 (0-7); 3.9 ± 3.5 
NRS > 5    67 (43) 
No. of days per month with considerable pain d                 6 (3-10) 
No. of days per month with impairment of usual activity     2 (0-4) 
SF-12 questionnaire 
 Physical Component Summary Score            41.6 ± 10.8 
Mental Component Summary Score            41.8 ± 10.6 
FSFI total score c            26.4 ± 5.6 
    
  
Note: Data are reported as mean ± standard deviation, n (%), or median (interquartile range). BMI = 
body mass index; FSFI = Female Sexual Function Index; GnRH = gonadotropin-releasing hormone; 
NRS = numeric rating scale (0-10); SF-12 = Short-form 12. 
a The sum does not add-up to the total because 17 women previously used more than one therapy.  
b Estrogen-progestins and progestins used previously were different from those used in the present 
study or were used with a different modality. 
NRS = 0-10-point Numeric Rating Scale.  
c Refers to 140 women because 17 did not have sexual intercourses at study entry.  
d Pain necessitating analgesics. 
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Table 2. Per-protocol analysis of pain symptoms, health-related quality of life and sexual functioning scores variation  
between baseline and 12-month evaluation (n = 133). 
   
    
 Symptom/Questionnaire  
Baseline 12-mo follow-up P value 
Dysmenorrhea 
   NRS 8 (8-10); 8.6 ± 4.8   0 (0-0); 1.2 ± 2.6 <.001 
NRS > 5 125 (94) 16 (12) <.001 
    Dyspareunia a 
   NRS     6 (0-8); 4.9 ± 3.4  0 (0-6); 2.6 ± 3.3 <.001 
NRS > 5  70 (59) 35 (30) <.001 
    Dyschezia 
   NRS  4 (0-8); 3.8 ± 3.9  0 (0-0); 1.2 ± 2.6 <.001 
NRS > 5  57 (43) 16 (12) <.001 
    Nonmenstrual pelvic pain 
   NRS  5 (0-7); 3.9 ± 3.6  0 (0-5); 2.5 ± 3.1 <.001 
NRS > 5  58 (44) 31 (23) <.001 
    No. of days per month with considerable pain b    7 (4-10) 0 (0-2) <.001 
    No. of days per month with impairment of usual activity  2 (0-4) 0 (0-0) <.001 
    SF-12 questionnaire 
   Physical Component Summary Score 41.4 ± 11.1         51.0 ± 8.7 <.001 
Mental Component Summary Score 41.9 ± 10.5         47.0 ± 10.0 <.001 
    FSFI total score a         26.4 ± 5.6         25.3 ± 6.1 .07 
        
    
Note: Data are reported as median (interquartile range), mean ± standard deviation, or n (%). Women who 
withdrew (n = 21) or underwent surgery (n = 3) before 12 month follow-up assessment were excluded. FSFI = 
Female Sexual Function Index; NRS = numeric rating scale (0-10); SF-12 = Short Form 12. 
a Fifteen women did not have sexual activity either at baseline or at the pre-planned follow-up evaluations.  
b Pain necessitating analgesics. 
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Table 3. Side-effects in estrogen-progestins and progestins users during the study period. 
        Side-effect                  3 mo (n = 151) 
                 6 mo 
(n = 142) 
                12 mo 
(n = 133) 
        
    None 28 (18) 29 (20) 27 (20)
    Headache 31 (20) 27 (19) 23 (17)
Spotting 55 (36) 36 (25) 30 (22) 
Weight gain 43 (28) 44 (31) 46 (34) 
Decreased libido 53 (35) 51 (36) 47 (35) 
Vaginal Dryness 37 (24) 35 (25)                     34 (25) 
Mood disorders 23 (15)                     22 (15)                     20 (15) 
    Breast tenderness 16 (10)                   12 (8)                  11 (8) 
Water retention                      6 (4)                    4 (3)                    4 (3) 
    Acne                      5 (3)                    5 (3)                    5 (4) 
Others                    10 (7)                    8 (6)                  10 (7) 
    Weight increase (Kg), mean ± SD 2.7 ± 0.5 2.0 ± 0.9 3.1 ± 1.2 
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Supplemental Table 1. Baseline ultrasonographic characteristics of study patients as 
assessed at transvaginal and/or transrectal examination. 
  
    Ultrasound findings 
Participants                               
(n = 157) 
 
  Ovarian endometriomas 
 Absent 93 (59%) 
Unilateral 51 (33%) 
Bilateral                        13 (8%) 
Largest cyst diameter (mm)   26 [19-38] 
  Deep invasive endometriosis 
 Absent 93 (59%) 
Rectovaginal 56 (36%) 
Other localizations 8 (5%) 
Largest lesion diameter (mm)   15 [10-20] 
  Adenomyosis 33 (21%) 
    
  Data is reported as number (percentage), or median [interquartile range]. 
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Supplemental Table 2. Comparison of baseline demographic and clinical characteristics of women who were or were not satisfied at 
12-month follow-up evaluation (n = 152) a. 
           
    Characteristic Satisfied                            (n = 95) 
Not satisfied b                   
(n = 57) P 
  
      Age (years) 32.9 ± 6.0 32.8 ± 5.5 0.94 
  Age at first diagnosis (years) 27.4 ± 5.2 27.0 ± 5.5 0.67 
  BMI (kg/m2) 21.1 ± 3.2 22.4 ± 3.8 0.03 
  Previous deliveries 23 (24%) 11 (19%) 0.55 
  Previous interventions for endometriosis 45 (47%)  32 (56%) 0.32 
  Lesions detected at transvaginal and/or transrectal ultrasonography 
     Deep invasive endometriosis 39 (41%) 24 (42%) 1.00 
  Endometriomas 37 (39%) 23 (40%) 0.87 
  Adenomyosis 24 (25%)  8 (14%) 0.15 
  Pain symptoms (NRS > 5) 
     Dysmenorrhea 88 (93%) 56 (98%) 0.26 
  Dyspareunia 48 (56%) c  36 (72%) d 0.10 
  Dyschezia 40 (42%) 24 (42%) 1.00 
  Non-menstrual pelvic pain 38 (40%) 28 (49%) 0.31 
  No. of days per month with considerable pain e   6 [3-10]   7 [3-15] 0.20 
  No. of days per month with impairment of usual activity 2 [0-4] 2 [1-5] 0.20 
  SF-12 questionnaire 
     Physical Component Summary Score 41.8 ±  11.2 41.2 ± 10.4 0.71 
  Mental Component Summary Score 43.0 ± 10.1 39.5 ± 11.4   0.048 
  FSFI total score 26.3 ± 5.3 c           26.4 ± 6.3 d 0.92 
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